USSTOCK.TODAY
Market Closed
Log in Sign up

Addex Therapeutics Ltd ADR(ADXN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

ADXN
ADXN
Addex Therapeutics Ltd ADR
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$3.40
+0.34 ▲ +11.11%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$3.40
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -8.81Insider Own ⓘ 0.03%Shs Outstand ⓘ 1.1MPerf Week ⓘ -35.73%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 1.1MPerf Month ⓘ 13.71%
Enterprise Value ⓘ 0.00BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 1.54%Short Float ⓘ 0.56%Perf Quarter ⓘ -31.17%
Income ⓘ -0.01BP/S ⓘ 36.04EPS this Y ⓘ -Inst Trans ⓘ 72.59%Short Ratio ⓘ 0.01Perf Half Y ⓘ -51.36%
Sales ⓘ 0.00BP/B ⓘ 1.53EPS next 5Y ⓘ -ROA ⓘ -115.52%Short Interest ⓘ 0.01MPerf YTD ⓘ -55.96%
Book/sh ⓘ 2.22P/C ⓘ 3.79EPS past 3/5Y ⓘ 46.11% 31.85%ROE ⓘ -151.69%52W High ⓘ -67.4% ($10.43)Perf Year ⓘ -62.05%
Cash/sh ⓘ 0.9P/FCF ⓘ -Sales past 3/5Y ⓘ -48.38% -44.27%ROIC ⓘ -362.44%52W Low ⓘ 32.81% ($2.56)Perf 3Y ⓘ -43.33%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ -3.77%Gross Margin ⓘ 52.26%Volatility(W/M) ⓘ 17.51% 9.85%Perf 5Y ⓘ -97.61%
Dividend TTM ⓘ -EV/Sales ⓘ 27.54Sales Y/Y TTM ⓘ -45.76%Oper. Margin ⓘ -3142.13%ATR (14) ⓘ 0.52Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 0.76EPS Q/Q ⓘ 18.74%Profit Margin ⓘ -8312.79%RSI (14) ⓘ 51.05Recom ⓘ 4.5
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 0.76Sales Q/Q ⓘ -71.39%SMA20 ⓘ 5.61% ($3.22)Beta ⓘ 1.55Target Price ⓘ $22.87
Payout ⓘ -Debt/Eq ⓘ 0.04Earnings ⓘ 2026/9/28SMA50 ⓘ 6.58% ($3.19)Rel Volume ⓘ 0.04Prev Close ⓘ $3.06
Employees ⓘ 3LT Debt/Eq ⓘ 0.01EPS/Sales Surpr. ⓘ -SMA200 ⓘ -40.83% ($5.75)Avg Volume(3M) ⓘ 0.51MPrice ⓘ $3.4
IPO ⓘ 2020/1/29Option/Short ⓘ No/YesTrades ⓘ 221Volume ⓘ 18,469Change ⓘ 11.11%
Company
ADXN ADXNAddex Therapeutics Ltd ADR | NASD | Biotechnology Deep dive

🧠 A Switzerland-based clinical-stage biotech developing small-molecule drugs targeting the **metabotropic glutamate receptor (mGluR)** family involved in brain signaling. Its lead pipeline candidate, dipraglurant, was originally aimed at Parkinson's disease-related side effects but has recently been repositioned toward recovery from stroke and traumatic brain injury, while its GABAB PAM program is being advanced through a partnership with Indivior. The company is a micro-cap listed on Nasdaq as an ADR.

Quote

Over the past 1 year, on the lower side

67% below its 1-year high.

Now $3.40
52w low$2.5652w high$10.43
52W Range11%
Volume ⓘ 18,469

Traded less than usual. That is 4% of its average volume.

D
Overall · many cautions
We judged 4 of the 8 questions below. 2 need caution.
No data for growth, earnings, outlook, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #553 of 598 in the industry

Based on market cap of $4M.

FAQ

FAQ

What kind of company is ADXN?

ADXN belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ADXN?

The market cap of ADXN is approximately $4M, ranking 5,644 within its sector.

What is the 52-week high and low for ADXN?

ADXN has recorded a 52-week high of $10.43 and a low of $2.56.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels